246 
FDA approves Regeneron antibody drug as first Ebola virus treatment
Bio Pharma Dive
OCTOBER 14, 2020
Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19
Antibody Related Topics 
Regeneron enlists Roche to boost production of COVID-19 antibody drug
Bio Pharma Dive
AUGUST 19, 2020
Together, the companies expect to make three and a half times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own
Join
thousands
INSIDERS
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Regeneron follows Lilly in asking for emergency approval of COVID-19 antibody drug
Bio Pharma Dive
OCTOBER 8, 2020
The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use
Merck pays Seattle Genetics $1.7B as antibody cancer drugs continue comeback
Bio Pharma Dive
SEPTEMBER 14, 2020
Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020
Regeneron’s Antibody Drug Becomes First Approved Treatment for Ebola
XTalks
OCTOBER 16, 2020
Inmazeb is a combination of three different antiviral monoclonal antibodies. The three monoclonal antibodies contained in Inmazeb are of similar structure; however, they bind to different, non-overlapping epitopes simultaneously on a glycoprotein found on the surface of the Ebola virus.
Lilly, with new data, seeks emergency clearance for COVID-19 antibody drug
Bio Pharma Dive
OCTOBER 7, 2020
The pharma is the first to seek emergency approval for this kind of treatment, and may quickly follow up with a second request after reporting promising data for a two-drug combination
Fujifilm to help Lilly make COVID-19 antibody drug
Bio Pharma Dive
OCTOBER 15, 2020
Lilly has asked the FDA for emergency clearance of the therapy, although a study safety review and an unrelated manufacturing inspection could complicate the request
Companies Press Ahead with COVID-19 Antibody Therapies
BioSpace
AUGUST 11, 2020
Although the world is eagerly awaiting news of an effective and safe vaccine against COVID-19, several companies are moving ahead testing therapeutic antibodies against the disease
U.S. Government Inks Antibody Cocktail Deal with AstraZeneca
BioSpace
OCTOBER 11, 2020
government program to advance COVID-19 vaccines and therapeutics, for a monoclonal antibody cocktail AstraZeneca signed a deal with Operation Warp Speed, the U.S.
UPMC Researchers Isolate Tiny Antibody That Neutralizes SARS-CoV-2 Virus
BioSpace
SEPTEMBER 15, 2020
The researchers used this antibody, which is 10-times smaller than a full-sized antibody and the smallest isolated biological molecule to date, to develop a potential therapeutic and prophylactic agent against the virus termed “Ab8
Roche Launches New COVID-19 Antibody Test to Support Vaccine Testing
BioSpace
SEPTEMBER 17, 2020
Roche launched its Elecsys Anti-SARS-CoV-2 S antibody test for markets that accept the CE Mark
Lilly offers first evidence that its antibody drug may help treat COVID-19
Bio Pharma Dive
SEPTEMBER 16, 2020
The results, from a mid-stage study of Lilly's drug, suggest treatment helped lower virus levels, but the degree to which patients benefited remains unclear
Regeneron says antibody drug may speed recovery of patients with mild COVID-19
Bio Pharma Dive
SEPTEMBER 29, 2020
Preliminary study data suggest the treatment could help people whose bodies aren't already fighting off infection, a finding the biotech is discussing with regulators
Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools
BioTech 365
OCTOBER 20, 2020
CHICAGO & MUNICH–(BUSINESS WIRE)–#Antibodies–Proteintech, the benchmark in antibodies, today announces the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies.
Oncotarget: A novel format for recombinant antibody-interleukin-2 fusion proteins
Scienmag
OCTOBER 23, 2020
and Alessandra Villa – alessandra.villa@philogen.com Oncotarget recently published “A novel format for recombinant antibody-interleukin-2 fusion proteins […].
Eli Lilly’s Antibody Therapy Against COVID-19 Reduced Hospitalization Rates
BioSpace
SEPTEMBER 15, 2020
Eli Lilly and Company announced interim proof-of-concept data from its BLAZE-1 Phase II clinical trial of LY-COV555, its neutralizing antibody therapy for COVID-19
Lilly to test COVID-19 antibody drug in unorthodox nursing home study
Bio Pharma Dive
AUGUST 3, 2020
Seeking fast answers in a pandemic, Lilly will use mobile RVs to set up infusion clinics at assisted living facilities, which have become COVID-19 hot spots
The Race for a Super-Antibody Against the Coronavirus
NY Times
OCTOBER 12, 2020
A network of scientists is chasing the pandemic’s holy grail: an antibody that protects against not just the virus, but also related pathogens that may threaten humans
Vir, GSK push coronavirus antibody drug straight into mid-stage tests
Bio Pharma Dive
AUGUST 31, 2020
The two companies, chasing rival treatments from Eli Lilly, Regeneron and more, aim to produce their first study results by the end of the year
Regeneron’s antibody cocktail active against coronavirus, cuts symptoms
Pharma Phorum
SEPTEMBER 30, 2020
Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. REGN-COV2 is a combination of two monoclonal antibodies and was designed to block infectivity of SARS-CoV-2 , the virus that causes COVID-19.
In recovering COVID-19 patients, antibodies fade quickly
Scienmag
OCTOBER 16, 2020
The blood of recovered patients contains antibodies that act against the coronavirus. Washington, DC – October 16, 2020 – In the absence of approved, effective treatments for COVID-19, some hospitals have been treating patients with severe COVID symptoms with blood plasma from recovering patients. While plasma hasn’t yet shown a benefit in randomized trials, some […]. Biology Microbiology Public Health Virology
Coronavirus: Monoclonal antibodies to begin UK trial
The Pharma Data
SEPTEMBER 14, 2020
Illustration of antibodies attacking the coronavirus. A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. What are monoclonal antibodies? Antibodies could be described as the “warriors” of the immune system. Image copyright.
Model-based Strategy to Guide the Choice of Clinical Doses for ADC
Pharma R&D Today
OCTOBER 14, 2020
Enter antibody-drug conjugates (ADCs). They have developed novel modelling and simulation-based tools to guide the choice of the most promising safe and efficacious dosing regimen of an innovative antibody drug conjugate.
IONTAS and FairJourney Biologics discover COVID-19 neutralizing antibodies
BioPharma Reporter
OCTOBER 1, 2020
Two leading clinical research organizations (CROs) say they have identified neutralizing antibodies with great potential for monoclonal antibody treatment.
Antibodies protect against wide range of influenza B virus strains
Scienmag
SEPTEMBER 24, 2020
Findings point the way to developing a broad-spectrum flu drug Credit: Yanan Dai Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St.
Lilly’s antibody therapy cuts hospitalisation rates in COVID-19
Pharma Phorum
SEPTEMBER 17, 2020
Eli Lilly has followed up supportive data from its Olumiant in COVID-19 with results of a study showing its antibody treatment could help prevent hospitalisation from the disease. The post Lilly’s antibody therapy cuts hospitalisation rates in COVID-19 appeared first on.
Regeneron targets September data drop from COVID-19 antibody trial
BioPharma Reporter
AUGUST 11, 2020
Regeneron Pharmaceuticals aims to post initial virology and biomarker data from clinical trials of its COVID-19 antibody cocktail next month. Bio Developments
Flexible targets help immune system make finely-tuned antibodies
Scienmag
AUGUST 24, 2020
An in-depth Garvan study of how the immune system generates effective antibodies provides new insights for vaccine design.
#news #biotech Chinese COVID-19 vaccine trial reports falling antibody titers
BioTech 365
OCTOBER 7, 2020
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Chinese COVID-19 vaccine trial reports falling antibody titers.Chinese COVID-19 vaccine trial reports falling antibody titers ntaylor Wed, 10/07/2020 – 08:57 from FierceBiotech: Biotech [link].
AstraZeneca's coronavirus antibody drug cocktail begins human tests as rivals slip
Bio Pharma Dive
AUGUST 25, 2020
The British pharma has started a Phase 1 trial amidst reports that competing programs from Regeneron and Eli Lilly haven't met their projected timelines
UCSF Researchers Develop Synthetic Llama Antibodies Against COVID-19
BioSpace
AUGUST 10, 2020
They are approximately 25% of the size of human antibodies and from other animals, and they appear to be the most potent anti-coronavirus compound that has been tested in the laboratory so far
Promising Early Data Prompts Eli Lilly to Seek EUA for COVID-19 Antibody Treatment
BioSpace
OCTOBER 6, 2020
Eli Lilly is seeking Emergency Use Authorization for its antibody therapy, LY-CoV555, for the treatment of high-risk patients with recently diagnosed mild-to-moderate coronavirus disease 2019 (COVID-19
Coronavirus antibodies tests 'put public at risk'
The Pharma Data
AUGUST 20, 2020
Poor regulation of antibodies tests – that could indicate if someone has had coronavirus – could be putting the public at risk, doctors have warned. It is still not known whether having antibodies will protect people from a second infection. Image copyright. Getty Images.
bioLytical Laboratories Announces Launch of INSTI® 1-Minute COVID-19 Antibody Test
BioTech 365
OCTOBER 15, 2020
INSTI® COVID-19 Antibody Test is bioLytical’s new one-minute test, detecting antibodies to SARS-CoV-2 with high accuracy. bioLytical has received CE Mark and approval to sell the test across Europe. bioLytical announced today that test kits are now available in Europe. … Continue reading → GlobeNewswire
Patients taking long-term opioids produce antibodies against the drugs
Scienmag
AUGUST 17, 2020
— University of Wisconsin-Madison scientists have discovered that a majority of back-pain patients they tested who were taking opioid painkillers produced anti-opioid antibodies. These antibodies may contribute to some of the negative side effects of long-term opioid use. Existing antibodies may also limit the benefit a patient receives from an anti-opioid vaccine, the […]. MADISON, Wis.
CR UK, AZ researchers pioneer new antibody maturation technique
The Pharma Data
SEPTEMBER 4, 2020
The technique has been used to generate a high-affinity antibody against Arginase 2, an enzyme implicated in major human diseases.
Roche, Regeneron ally to triple supply of COVID-19 antibody cocktail
BioPharma Reporter
AUGUST 20, 2020
Roche agrees to distribute Regeneronâs COVID-19 antibody combination outside the US, more than tripling manufacturing capacity. Downstream Processing
Vir Bio and GSK Join the Race for a COVID-19 Monoclonal Antibody Therapy
BioSpace
AUGUST 30, 2020
Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19
Patients with recently discovered antibodies have more severe myasthenia gravis
Scienmag
AUGUST 18, 2020
Global Monoclonal Antibodies Market to Surpass US$ 368.8 Billion by 2027, Says Coherent Market Insights (CMI)
BioTech 365
OCTOBER 16, 2020
SEATTLE–(BUSINESS WIRE)–#Antibodies–According to Coherent Market Insights, the global monoclonal antibodies market is estimated to be valued at US$ 143.5
Let's personalize your content